Daiichi Sankyo Co., Ltd.: Innovation Leads the Future

Daiichi Sankyo Company Limited (TYO: 4568) is a globally renowned multinational pharmaceutical company known for its exceptional research and development capabilities and extensive portfolio of medical products. As a company dedicated to human health, Daiichi Sankyo has achieved remarkable success not only in pharmaceutical research and development but also in the development of medical devices and related products. Its headquarters are located in Tokyo, Japan, and its official website is www.daiichisankyo-hc.co.jp .

Daiichi Sankyo's mission is to improve the quality of life for patients worldwide through innovative medicines and healthcare services. This goal drives the company's global business expansion and research investment. As a pharmaceutical company with a long and rich history, Daiichi Sankyo has always been at the forefront of the industry, driving progress in medical science and earning widespread recognition and trust globally.

The company's origin and development history

Daiichi Sankyo's history dates back to the late 19th century. Sankyo Pharmaceutical Co., Ltd. was founded in 1899 and renamed "Sankyo Pharmaceutical" in 1900. After more than a century of development, Sankyo Pharmaceutical gradually grew into one of Japan's and the world's leading pharmaceutical companies. In 2005, Sankyo Pharmaceutical merged with Daiichi Pharmaceutical to form Daiichi Sankyo Co., Ltd., further solidifying its position in the global pharmaceutical industry.

Since its inception, Daiichi Sankyo has consistently focused on new drug research and development and technological innovation. By integrating the resources and technological advantages of its two parent companies, the company continuously enhances its competitiveness. Particularly in the fields of cardiovascular disease, oncology treatment, and anti-infective drugs, Daiichi Sankyo's research achievements have received high praise from the international community. Furthermore, the company is actively expanding into emerging technology fields such as gene therapy and precision medicine, striving to achieve a leading position in the future development of medicine.

Core business areas

Daiichi Sankyo's core businesses encompass the research, development, production, and sales of pharmaceuticals, as well as the development of medical devices and related products. The following is a detailed introduction to the company's main business areas:

1. Pharmaceutical research and development and manufacturing

As a research-driven pharmaceutical company, Daiichi Sankyo boasts a strong portfolio across multiple therapeutic areas. The company focuses on developing innovative medicines to address unmet medical needs. Here are some key areas:

• Cardiovascular diseases: Daiichi Sankyo is a leader in the treatment of cardiovascular diseases such as hypertension and hyperlipidemia. For example, the antihypertensive drugs and statins developed by the company are widely used in clinical practice.
• Cancer treatment: In recent years, the company has made significant breakthroughs in the research and development of anti-cancer drugs, especially in targeted therapies for breast cancer and lung cancer.
• Anti-infective drugs: Daiichi Sankyo has also accumulated extensive experience in the field of antibiotics and antiviral drugs, providing important support for the global fight against infectious diseases.
• Central Nervous System Disorders: The company has developed a series of highly effective drugs for mental illnesses such as depression and anxiety, helping patients improve their quality of life.

In addition to traditional medicines, Daiichi Sankyo is also actively exploring emerging fields such as biologics and gene therapy, striving to provide patients with more diverse treatment options.

2. Medical devices and related products

Daiichi Sankyo not only focuses on pharmaceutical research and development but also has made significant achievements in the field of medical devices and related products. Through independent research and development or collaborations with other companies, the company has launched a variety of innovative medical devices for diagnosis, treatment, and rehabilitation. These products include, but are not limited to:

• Portable medical devices used to monitor a patient's health status.
• Surgical aids improve surgical efficiency and safety.
• Rehabilitation training equipment helps patients restore their physical functions.

By combining pharmaceuticals with medical devices, Daiichi Sankyo is able to provide comprehensive solutions for medical institutions and patients.

Globalization strategy and international cooperation

As a multinational corporation, Daiichi Sankyo understands the importance of globalization. The company continuously expands its global influence by establishing overseas branches, acquiring local companies, and building partnerships.

Currently, Daiichi Sankyo has R&D centers and manufacturing bases in multiple regions including Asia, Europe, and North America, ensuring a rapid response to the needs of different markets. At the same time, the company actively participates in international clinical trials and collaborates with leading research institutions and universities worldwide to jointly advance the development of pharmaceutical science.

It's worth noting that Daiichi Sankyo places great emphasis on collaborations with local companies. For example, in the Chinese market, the company has established strategic alliances with several pharmaceutical companies to jointly develop drugs tailored to the needs of Chinese patients. This collaborative model not only promotes technological exchange but also brings more business opportunities to the company.

Sustainable Development and Social Responsibility

Daiichi Sankyo has always considered sustainable development and social responsibility as important components of its corporate development. The company fulfills its social commitments in various ways:

• Environmental protection: Daiichi Sankyo is committed to reducing carbon emissions and waste generation during the production process and promoting the concept of green manufacturing.
• Employee care: The company provides employees with a good working environment and development opportunities, and encourages a diverse and inclusive culture.
• Public Welfare: Daiichi Sankyo actively participates in various public welfare activities, supports the development of medical and health services, and helps vulnerable groups obtain better medical services.

In addition, Daiichi Sankyo has established a special fund to support medical research and education projects and cultivate future medical professionals.

Official website: www.daiichisankyo-hc.co.jp

Daiichi Sankyo's official website ( www.daiichisankyo-hc.co.jp ) is an important window into the company. The website not only showcases Daiichi Sankyo's history, vision, and core values, but also provides a wealth of business information and research updates.

Visitors can obtain the following information from the official website:

• Company profile and organizational structure.
• Latest research and development results and product information.
• Global market business distribution and cooperation cases.
• Sustainable development reports and social responsibility activities.
• Investor relations materials, including financial statements and shareholder meeting announcements.

In addition, the official website features a career development section, providing recruitment information and application channels for those aspiring to join Daiichi Sankyo. Both industry professionals and the general public can use this platform to gain a deeper understanding of Daiichi Sankyo and its contributions to the pharmaceutical field.

Looking to the future

With the aging global population and rising incidence of chronic diseases, the pharmaceutical industry faces unprecedented opportunities and challenges. Daiichi Sankyo will continue to uphold its philosophy of "Innovation Leading the Future," increase investment in research and development, expand its business scope, and bring more benefits to patients worldwide.

Over the next few years, Daiichi Sankyo plans to focus on developing the following areas:

• Accelerate research into gene therapy and cell therapy to explore the possibility of curative drugs.
• Deepen digital transformation and optimize drug development processes by leveraging artificial intelligence and big data technologies.
• Strengthen relationships with global partners to jointly address public health challenges.
• Expand business coverage in emerging markets, especially in Asia and Africa.

In conclusion, Daiichi Sankyo Co., Ltd. is not only a global leader in the pharmaceutical industry, but also a vital force driving progress in human health. With its outstanding R&D capabilities, global vision, and strong sense of social responsibility, Daiichi Sankyo is poised to continue writing a glorious chapter in the future.